title: Leishmaniasis in solid organ and hematopoietic stem cell transplant recipients.
abstract: Leishmaniasis occurs in <1% of solid organ and hematopoietic stem cell transplant recipients in endemic countries in which transplants are performed. Visceral leishmaniasis (VL) makes up the bulk of reported cases. The onset generally occurs months after transplantation and the mode of acquisition is often impossible to determine, but de novo vector-borne infection and reactivation of inapparent infection are thought to be the principal means. The potential role of clinically inapparent donor infection is uncertain and screening is not currently recommended, nor is it recommended for recipients from endemic areas, some of whom may have detectable circulating protozoan nucleic acid. While transplant recipients with VL often present with the non-specific findings of fever and cytopenia, the additional presence of hepatosplenomegaly in patients from endemic areas should lead to a directed diagnostic evaluation with bone marrow examination and PCR testing of marrow and peripheral blood having a high yield. Management may often be complicated by the presence of concomitant infections. A lipid formulation of amphotericin B is the preferred treatment, especially for VL, but the relapse rate in transplant recipients is approximately 25%. PCR monitoring of blood for either secondary prophylaxis or preemptive therapy requires further study.
authors: Division of Infectious Diseases, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
authors: Kiran
authors: K
authors: Gajurel
authors: University of Iowa, Carver College of Medicine, Iowa City, IA, USA.
authors: Reshika
authors: R
authors: Dhakal
authors: Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA.
authors: Stan
authors: S
authors: Deresinski
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D007896:Leishmaniasis / Q000209:etiology*; D016377:Organ Transplantation / Q000009:adverse effects*
keywords: 
  Leishmania
  ; amphotericin B; hematopoietic; leishmaniasis; transplant